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Background: Berberine hydrochloride is a conventional component in Chinese medicine, 
and is characterized by a diversity of pharmacological effects. However, due to its hydrophobic 
properties, along with poor stability and bioavailability, the application of berberine hydrochlo-
ride was hampered for a long time. In recent years, the pharmaceutical preparation of berberine 
hydrochloride has improved to achieve good prospects for clinical application, especially for 
novel nanoparticulate delivery systems. Moreover, anticancer activity and novel mechanisms have 
been explored, the chance of regulating glucose and lipid metabolism in cancer cells showing 
more potential than ever. Therefore, it is expected that appropriate pharmaceutical procedures 
could be applied to the enormous potential for anticancer efficacy, to give some new insights 
into anticancer drug preparation in Chinese medicine.
Methods and results: We accessed conventional databases, such as PubMed, Scope, and Web 
of Science, using “berberine hydrochloride”, “anti-cancer mechanism”, and “nanoparticulate 
delivery system” as search words, then summarized the progress in research, illustrating the 
need to explore reprogramming of cancer cell metabolism using nanoparticulate drug delivery 
systems.
Conclusion: With increasing research on regulation of cancer cell metabolism by berberine 
hydrochloride and troubleshooting of issues concerning nanoparticulate delivery preparation, 
berberine hydrochloride is likely to become a natural component of the nanoparticulate delivery 
systems used for cancer therapy. Meanwhile, the known mechanisms of berberine hydrochloride, 
such as decreased multidrug resistance and enhanced sensitivity of chemotherapeutic drugs, 
along with improvement in patient quality of life, could also provide new insights into cancer 
cell metabolism and nanoparticulate delivery preparation.
Keywords: berberine hydrochloride, anticancer mechanisms, nanoparticulate drug progress
Introduction
Berberine hydrochloride is an isoquinoline alkaloid (see Figure 1) isolated from 
a   variety of Chinese herbs, including Coptidis rhizoma, Phellodendron chinense 
  schneid, and Phellodendron amurense, and has diverse pharmacological actions. It 
has antidiabetic and antilipid peroxidation activity, as well as an anti-atherosclerotic 
action, and also has neuroprotective properties and improves polycystic ovary 
syndrome.1–5 Berberine hydrochloride is widely used as an antibacterial, antifungal, 
and   anti-inflammatory drug, and has been used as a gastrointestinal remedy for 
thousands of years in China.6,7
Nowadays, the antiproliferative activity and sensitivity enhancement of berberine 
hydrochloride in various cancer cell lines8–14 have led to further research interest in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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this compound.15–17 Its antineoplastic properties include 
induction of apoptosis and cell cycle arrest, along with 
inhibition of cell migration and invasion via regulation of 
multiple pathways.18–21 The potential targets of berberine 
hydrochloride include reactive oxygen species generation, 
mitochondrial function, DNA topoisomerase inhibition, 
DNA or RNA binding, the estrogen receptor, matrix metal-
loproteinase regulation, p53 activation, and NF-kappa B 
signal activation.10,22–26 However, it has poor water solubility 
caused by a quarternary amine, resulting in a low effective 
concentration and limited absorption in the gastrointestinal 
tract, which seriously limits its application and development 
as a pharmaceutical preparation. Furthermore, it has a risk 
of adverse reactions associated with intramuscular and 
intravenous administration, such as anaphylactic shock and 
drug rash, so a novel drug delivery system to improve the 
solubility and bioavailability of berberine hydrochloride has 
become a matter of urgency.
During the rapid development of nanotechnology, 
increasing attention has been paid to nanoparticulate drug 
delivery systems.27–29 Modern nanoparticulate dosage 
forms including polymeric nanoparticles, nanocapsules, 
liposomes, solid lipid nanoparticles, and nanoemulsions, 
all of which can improve drug solubility. In general, 
nanoparticulate drug delivery enhances solubility and 
bioavailability, improving pharmacological activity and 
tissue macrophage distribution, while preventing physical 
and chemical degradation.30,31 Therefore, we combined the 
good anticancer efficacy of berberine hydrochloride with 
a novel nanoparticulate drug delivery system to obtain a 
promising anticancer agent.
This review discusses anticancer mechanisms, with 
  particular reference to regulation of glucose and lipid metabo-
lism, and describes a novel drug delivery system for berberine 
hydrochloride, aiming to provide new insights into Chinese 
medicine preparations with anticancer activity.
Anticancer mechanisms of 
berberine hydrochloride
The potential antitumor activity of berberine hydrochloride 
has always been a subject of considerable interest because 
of its known ability to interact with nucleic acids. Its ability 
to bind specifically to oligonucleotides and to stabilize DNA 
triplexes or G-quadruplexes via telomerase and topoisomerase 
inhibition accounts for its antiproliferative activity.32,33 The 
predominant interaction between berberine hydrochloride and 
double-stranded or single-stranded DNA is electrostatic, and 
can be quantified in terms of the Hill model of cooperative 
interactions.34 Recent novel mechanisms have a higher 
propensity for autophagy and autophagic regulators. Wang 
et al found that berberine hydrochloride induced autophagic 
cell death which was diminished by 3-methyladenine, a cell 
death inhibitor, in the human hepatic carcinoma cell lines 
HepG2 and MHCC97-L, through activation of beclin-1 and 
inhibition of the mTOR signaling pathway.35 In addition, 
the autophagic marker, microtubule-associated protein-1 
light chain 3 (LC3) was modified after administration of 
berberine hydrochloride in the human A549 lung cancer cell 
line, accompanied by shrinkage of tumor volume in a Lewis 
lung carcinoma model in mice, all of which indicates that 
autophagy might be important in cancer cell death.36
In addition to autophagy and its interaction with nucleic 
acid, the hypoglycemic and hypolipidemic effects of berberine 
hydrochloride also point to a relationship between adipose 
tissue/adipocytes and tumorigenesis, through upregulation 
of mRNA and protein levels in adipose tissue, including 
peroxisome proliferator-activated receptor (PPAR) α, β, 
and γ, CDK9, and cyclin T1.3 Adipose tissue and adipocytes 
have a significant role in the tumor microenvironment,37 and 
SPARC (secreted protein acidic and rich in cysteine), an 
adiposity inhibitor, was suggested by Nagaraju and Sharma38 
to be a potent anticancer molecule, and human adipose tissue-
derived stem cells are known to be a source of carcinoma-
associated fibroblasts in the presence of transforming 
growth factor β1.39 Further, adipose tissue-derived vascular 
endothelial growth factor and leptin promote adipogenesis in 
order to maintain the tumor microenvironment.40 Hirano et al 
have also suggested the existence of undefined factors derived 
from cancer cells which promote adipogenesis, further 
indicating a potential relationship between adipogenesis and 
development of cancer.41 In clinical lipofilling procedures 
undertaken for patients with breast cancer, there is an 
urgent need to clarify the issue of cancer recurrence and 
adipogenesis.42 The adipogenesis positive regulator, PPARγ, 
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overexpressed in ERBB2-positive breast cancer cells, enables 
fatty acid synthesis, mainly to support energy demands 
and cell survival.43 Therefore, less toxic PPARγ agonists 
or antagonists, including berberine hydrochloride, are 
regarded as potential agents for improving adipose breast 
tissue and decreasing breast cancer risk, as well as suppressing 
proliferation and invasion of cancer cells.44 By inhibiting 
PPARγ protein expression and increasing PPARα mRNA 
levels, berberine hydrochloride has been shown to improve 
free fatty acid-induced insulin resistance in myotubes, and to 
suppress adipogenesis in white preadipocytes in humans and 
hepatic insulin resistance in diabetic hamsters.2,45,46 Berberine 
hydrochloride also prevented wasting of epididymal adipose 
tissue and ameliorated cancer cachexia in colon 26/clone 
20-transplanted mice and colon 26/clone 20 cells,47 further 
highlighting the beneficial effect of this compound on adipose 
tissue in the tumor microenvironment.
Working as a potential natural compound in cancer 
therapy via its interaction with nucleic acid and regulation 
of cancer cells, as well as induction of autophagy, berberine 
hydrochloride augments the effects of chemotherapy/
radiotherapy and has shown good prospects in cancer 
treatment.11 After the novel mechanisms by which it interferes 
with the development of adipose tissue and adipocyte 
metabolism in the tumor microenvironment were investigated, 
the efficacy and potential applications of berberine   
hydrochloride were highlighted and emphasized. Moreover, 
its extensive occurrence in various plant species and low 
toxicity suggest that berberine hydrochloride has the potential 
to become an effective antitumor agent in the future.
Nanoparticulate delivery systems
Reports on nanoparticulate delivery systems for berberine 
hydrochloride can be divided into three types, ie, solid lipid 
nanoparticles, nanoemulsions, and liposomes. Preparation, 
characterization, experimental design methods, and in vivo 
and in vitro studies are summarized here.
The first nanoparticulate delivery system uses a con-
ventional rotary-evaporated film-ultrasonication method to 
make solid lipid nanoparticles of berberine hydrochloride 
(BH-SLN). These have good stability, a mean diameter of 
60.5 nm, a zeta potential of 29.7 mV , drug loading of 8.69%, 
and an entrapment ratio of 97.58%.48 Certain other factors 
have a direct impact on actual amount and quality of lipo-
some entrapment, including preparation and manufacturing 
methods, and types of excipients used and particle size. 
Entrapment is defined as the fraction of the initial solution 
remaining within the liposomes, which is the key factor in 
clinical application.49 Wang et al established the method 
of coagulation centrifugation to determine the entrapment 
  efficiency of BH-SLN.50 A saturated aqueous solution of 
sodium chloride 0.05 mL in BH-SLN 0.5 mL was determined 
by high-pressure liquid chromatography, and then centri-
fuged at 12,000 rpm for 10 minutes to obtain the supernatant. 
The results show that coagulation centrifugation was rapid 
and accurate.
The second delivery system is berberine   hydrochloride 
nanoemulsion, made by isopropyl myristate, EL40, 
and   glycerin using pseudoternary phase diagrams. The 
nanoemulsion is a clear transparent solution with an average 
particle diameter of 56.8 nm.51 Small spherical drops are seen 
under electron microscopy, with a stable content and diameter 
even under high humidity and temperature conditions, along 
with strong light, 92.5% humidity, a temperature range of 
40°C–60°C, and (4500 ± 500) LX.
The last system is a liposomal one, and there are 
several approaches used to prepare berberine hydrochloride 
liposomes, including the thin film evaporation method, 
the active loading method, and a combination of the thin 
film evaporation and active loading methods. The thin film 
evaporation process could achieve a higher encapsulation 
efficiency, and the optimum manufacturing processes are 
characterized by 60°C of hatched temperature, 30 minutes 
of time, and 3.3 mg/mL of cholesterol concentration.52 
An active loading method is better than passive loading 
with a higher entrapment efficiency.53 There are several 
factors to be considered, including addition sequence, 
incubation time, incubation temperature, pH value of the 
external water phase, and the particle size of the liposome. 
Changing the addition sequence can also achieve different 
entrapment efficiencies, as can increasing incubation time 
and temperature and decreasing the particle size.53 Chen et al 
used different individual variables and an orthogonal design 
to obtain the optimal preparation conditions for berberine 
hydrochloride liposomes, including incubation time and 
incubation temperature, proportional weights of drug and 
lipids, soybean phosphatidylcholine, and cholesterol.54 The 
results indicated that the average encapsulation efficiency 
of the optimized liposome was 78.51% ± 2.45%, with a 
size range of 2.2–3.5 µm. Based on the uniform design, 
berberine hydrochloride liposomes were prepared by thin 
film evaporation and an active loading method.55 An optimal 
formulation was established and a high encapsulation 
efficiency of 79.33% was obtained with a drug loading International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ratio of 30.21 and a size range of 2.2–3.8 µm. In vivo and 
in vitro studies were carried out to investigate the way in 
which liposomal berberine hydrochloride works. Gou et al 
studied the effects of berberine hydrochloride liposomes 
on the combination of impaired glucose tolerance and 
hyperlipidemia, suggesting that glucose and lipid metabolism 
was interfered with and progression from hyperlipidemia to 
type 2 diabetes was also prevented.56
Conclusion
Studies of the molecular mechanisms by which berberine 
hydrochloride affects lipid and glucose metabolism warrant 
further attention. Additionally, with the increasing research 
on reprogramming of cancer cell metabolism, including 
inhibition of glycolysis, impairment of mitochondrial 
  function, and suppression of cell anabolism, it could be 
  possible to reverse abnormal cancer cell metabolism in vari-
ous ways, including blocking formation of the cell membrane 
and synthesis of macromolecules, and inhibiting growth and 
proliferation of cancer cells. During the process of interfering 
with cancer cell reprogramming, because of the alteration in 
the physiological properties of the cell, multidrug resistance, 
sensitivity of chemotherapeutic drugs, and patient quality of 
life could be ameliorated, which indicates the potential of 
berberine hydrochloride as an adjuvant drug in antineoplastic 
treatment. With effective troubleshooting of issues such as 
the hydrophobic properties, poor stability, and bioavailability 
of berberine hydrochloride, research on nanoparticulate 
delivery systems for this compound is being vigorously 
pursued. Furthermore, investigations in this field are likely 
to provide new insights into anticancer drug preparation in 
Chinese medicine.
Acknowledgments
This study was supported by the Macao Science and 
Technology Development Fund (029/2007/A2) and 
University of Macau Research Fund (UL016A/09-Y2/CMS/
WYT01/ICMS).
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Lee IA, Hyun YJ, Kim DH. Berberine ameliorates TNBS-induced colitis 
by inhibiting lipid peroxidation, enterobacterial growth and NF-kappaB 
activation. Eur J Pharmacol. 2010;648(1–3):162–170.
2.  Liu X, Li G, Zhu H, et al. Beneficial effect of berberine on hepatic 
insulin resistance in diabetic hamsters possibly involves in SREBPs, 
LXRalpha and PPARalpha transcriptional programs. Endocr J. 2010; 
57(10):881–893.
  3.  Zhou J, Zhou S. Berberine regulates peroxisome proliferator-activated 
receptors and positive transcription elongation factor b expression in 
diabetic adipocytes. Eur J Pharmacol. 2010;649(1–3):390–397.
  4.  Wu M, Wang J, Liu LT. Advance of studies on anti-atherosclerosis 
mechanism of berberine. Chin J Integr Med. 2010;16(2):188–192.
  5.  Zhao L, Li W, Han F, et al. Berberine reduces insulin resistance induced 
by dexamethasone in theca cells in vitro. Fertil Steril. 2011;95(1): 
461–463.
  6.  Remppis A, Bea F, Greten HJ, et al. Rhizoma coptidis inhibits LPS-
induced MCP-1/CCL2 production in murine macrophages via an 
AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010; 
2010:194896.
  7.  Liu F, Liang HL, Xu KH, Tong LL, Tang B. Supramolecular interaction 
of ethylenediamine linked beta-cyclodextrin dimer and berberine 
  hydrochloride by spectrofluorimetry and its analytical application. 
Talanta. 2007;74(1):140–145.
  8.  Choi MS, Yuk DY, Oh JH, et al. Berberine inhibits human   neuroblastoma 
cell growth through induction of p53-dependent apoptosis. Anticancer 
Res. 2008;28(6A):3777–3784.
  9.  Ho YT, Lu CC, Yang JS, et al. Berberine induced apoptosis via 
promoting the expression of caspase-8, -9 and -3, apoptosis-inducing 
factor and endonuclease G in SCC-4 human tongue squamous 
  carcinoma cancer cells. Anticancer Res. 2009;29(10):4063–4070.
  10.  Hsu WH, Hsieh YS, Kuo HC, et al. Berberine induces apoptosis in 
SW620 human colonic carcinoma cells through generation of reactive 
oxygen species and activation of JNK/p38 MAPK and FasL. Arch 
Toxicol. 2007;81(10):719–728.
  11.  Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast 
cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur 
J Pharmacol. 2010;645(1–3):70–78.
  12.  Auyeung KK, Ko JK. Coptis chinensis inhibits hepatocellular carcinoma 
cell growth through nonsteroidal anti-inflammatory drug-activated gene 
activation. Int J Mol Med. 2009;24(4):571–577.
  13.  Yu FS, Yang JS, Lin HJ, et al. Berberine inhibits WEHI-3 leukemia 
cells in vivo. In Vivo. 2007;21(2):407–412.
  14.  James MA, Fu H, Liu Y, Chen DR, You M. Dietary administration 
of berberine or Phellodendron amurense extract inhibits cell cycle 
  progression and lung tumorigenesis. Mol Carcinog. 2011;50(1):1–7.
  15.  Kim DW, Ahan SH, Kim TY. Enhancement of arsenic trioxide (As(2)
O(3))-mediated apoptosis using berberine in human neuroblastoma 
SH-SY5Y cells. J Korean Neurosurg Soc. 2007;42(5):392–399.
  16.  Shen N, Li CN, Huan Y, Shen ZF. [Advances of the mechanism study on 
berberine in the control of blood glucose and lipid as well as metabolism 
disorders.] Yao Xue Xue Bao. 2010;45(6):699–704. [Chinese.]
  17.  Zhang Q, Xiao X, Feng K, et al. Berberine moderates glucose and lipid 
metabolism through multipathway mechanism. Evid Based Complement 
Alternat Med. September 26, 2010. [Epub ahead of print].
  18.  Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Berberine, an 
isoquinoline alkaloid, inhibits melanoma cancer cell migration by 
reducing the expressions of cyclooxygenase-2, prostaglandin E and 
prostaglandin E receptors. Carcinogenesis. 2011;32(1):86–92.
  19.  Li-Weber M. Targeting apoptosis pathways in cancer by Chinese 
medicine. Cancer Lett. August 2, 2010. [Epub ahead of print].
  20.  Tsang CM, Lau EP, Di K, et al. Berberine inhibits Rho GTPases and 
cell migration at low doses but induces G2 arrest and apoptosis at high 
doses in human cancer cells. Int J Mol Med. 2009;24(1):131–138.
  21.  Zhang X, Gu L, Li J, et al. Degradation of MDM2 by the interaction 
between berberine and DAXX leads to potent apoptosis in MDM2-
overexpressing cancer cells. Cancer Res. 2010;70(23):9895–9904.
  22.  Meeran SM, Katiyar S, Katiyar SK. Berberine-induced apoptosis in 
human prostate cancer cells is initiated by reactive oxygen species 
generation. Toxicol Appl Pharmacol. 2008;229(1):33–43.
  23.  Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, 
Aggarwal BB. Berberine modifies cysteine 179 of IkappaBalpha 
kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic 
gene   products, and potentiates apoptosis. Cancer Res. 2008;68(13): 
5370–5379.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1777
Nanoparticulate delivery of berberine hydrochloride
  24.  Qin Y, Pang JY, Chen WH, Zhao ZZ, Liu L, Jiang ZH. Inhibition of 
DNA topoisomerase I by natural and synthetic mono- and dimeric 
protoberberine alkaloids. Chem Biodivers. 2007;4(3):481–487.
  25.  Lin JP, Yang JS, Wu CC, et al. Berberine induced down-regulation of 
matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells 
(SNU-5) in vitro. In Vivo. 2008;22(2):223–230.
  26.  Katiyar SK, Meeran SM, Katiyar N, Akhtar S. p53 Cooperates 
berberine-induced growth inhibition and apoptosis of non-small cell 
human lung cancer cells in vitro and tumor xenograft growth in vivo. 
Mol Carcinog. 2009;48(1):24–37.
  27.  Yang RS, Chang LW, Yang CS, Lin P. Pharmacokinetics and 
physiologically-based pharmacokinetic modeling of nanoparticles.   
J Nanosci Nanotechnol. 2010;10(12):8482–8490.
  28.  Seigneuric R, Markey L, Nuyten DS, et al. From nanotechnology to 
nanomedicine: Applications to cancer research. Curr Mol Med. 2010; 
10(7):640–652.
  29.  Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro- and 
nanocarrier-mediated lung targeting. Expert Opin Drug Deliv. 2010; 
7(7):781–794.
  30.  Kumar CSSR. Nanotechnology tools in pharmaceutical R&D. Mater 
Today. 2010;12:24–30.
  31.  Raffa V , Vittorio O, Riggio C, Cuschieri A. Progress in nanotechnology 
for healthcare. Minim Invasive Ther Allied Technol. 2010;19(3): 
127–135.
  32.  Maiti M, Kumar GS. Polymorphic nucleic acid binding of   bioactive 
  isoquinoline alkaloids and their role in cancer. J Nucleic Acids. 
December 15, 2009. [Epub ahead of print].
  33.  Bhadra K, Kumar GS. Therapeutic potential of nucleic acid-binding 
isoquinoline alkaloids: Binding aspects and implications for drug 
design. Med Res Rev. January 14, 2010. [Epub ahead of print].
  34.  Tian X, Song Y, Dong H, Ye B. Interaction of anticancer herbal drug 
berberine with DNA immobilized on the glassy carbon electrode. 
Bioelectrochemistry. 2008;73(1):18–22.
  35.  Wang N, Feng Y, Zhu M, et al. Berberine induces autophagic cell 
death and mitochondrial apoptosis in liver cancer cells: The cellular 
mechanism. J Cell Biochem. 2010;111(6):1426–1436.
  36.  Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing 
effect of radiation and berberine combined treatment in lung cancer: 
The contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 
2008;70(2):529–542.
  37.  Masson O, Prebois C, Derocq D, et al. Cathepsin-d, a key protease in 
breast cancer, is up-regulated in obese mouse and human adipose tissue, 
and controls adipogenesis. PLoS One. 2011;6(2):e16452.
  38.  Nagaraju GP, Sharma D. Anti-cancer role of SPARC, an inhibitor of 
adipogenesis. Cancer Treat Rev. January 13, 2011. [Epub ahead of 
print].
  39.  Jotzu C, Alt E, Welte G, et al. Adipose tissue-derived stem cells 
differentiate into carcinoma-associated fibroblast-like cells under the 
influence of tumor-derived factors. Anal Cell Pathol. 2010;33(2): 
61–79.
  40.  Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. 
Cytokine Growth Factor Rev. 2009;20(3):193–201.
  41.  Hirano T, Morii H, Nakazawa K, et al. Enhancement of adipogenesis 
induction by conditioned media obtained from cancer cells. Cancer 
Lett. 2008;268(2):286–294.
  42.  Lohsiriwat V, Curigliano G, Rietjens M, Goldhirsch A, Petit JY. 
Autologous fat transplantation in patients with breast cancer:   “silencing” 
or “fueling” cancer recurrence? Breast. February 4, 2011. [Epub ahead 
of print].
  43.  Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. 
Peroxisome proliferator-activated receptor-gamma protects ERBB2-
positive breast cancer cells from palmitate toxicity. Breast Cancer Res. 
2009;11(2):R16.
  44.  Carter JC, Church FC. Obesity and breast cancer: The roles of 
peroxisome proliferator-activated receptor-gamma and plasminogen 
activator inhibitor-1. PPAR Res. 2009;2009:345320.
  45.  Chen Y, Li Y, Wang Y, Wen Y, Sun C. Berberine improves 
  free-fatty-acid-induced insulin resistance in L6 myotubes through 
inhibiting peroxisome proliferator-activated receptor gamma and fatty 
acid transferase expressions. Metabolism. 2009;58(12):1694–1702.
  46.  Hu Y, Davies GE. Berberine inhibits adipogenesis in high-fat 
  diet-induced obesity mice. Fitoterapia. 2010;81(5):358–366.
  47.  Iizuka N, Hazama S, Yoshimura K, et al. Anticachectic effects of the 
natural herb Coptidis rhizoma and berberine on mice bearing colon   
26/clone 20 adenocarcinoma. Int J Cancer. 2002;99(2):286–291.
  48.  Hou J, Zhou S. Optimization of the preparation technology of   berberine 
hydrochloride solid lipid nanoparticles by orthogonal experiment. China 
Pharmacy. 2008;19(15):1150–1152.
  49.  Gruner SM, Lenk RP, Janoff AS, Ostro MJ. Novel multilayered lipid 
vesicles: Comparison of physical characteristics of multilamellar 
  liposomes and stable plurilamellar vesicles. Biochemistry. 1985;24(12): 
2833–2842.
  50.  Wang Y, Zheng J, Xu B, Wang H, Deng Y, Bi D. Determination of entrap-
ment efficiency of berberine hydrochloride solid lipid nanoparticles 
by coagulation-centrifuge method. Journal of Zhengzhou University 
(Medical Sciences). 2009;44(1):188–189.
  51.  Sun H, Ouyang W. Preparation and physicochemical characteristics of 
berberine hydrochloric nanoemulsion. Chinese Traditional and Herbal 
Drugs. 2007;38(10):1476–1480.
  52.  Zhang F, An X. Study on preparation of berberine hydrochloride 
liposomes. Journal of Nanjing Normal University (Natural Science). 
2006;29(1):56–58.
  53.  Deng Y, Wang S, Wu Q, Wan F, Lei X, Wang Z. Preparation of berberine 
hydrochloride liposomes by active loading method. Chinese Pharma-
ceutical Journal. 2004;39(1):40–42.
  54.  Chen J, Tan L, Li W, Li G. Study on the preparation process of berberine 
hydrochloride liposomes by orthogonal design. Journal of Practical 
Medical Techniques. 2007;14(14):1868–1870.
  55.  Tan L, Li G, Chen J, Su W, Rong K. Application of uniform design for 
preparation of berberine hydrochloride liposomes. Journal of Practical 
Medical Techniques. 2007;14(11):1385–1386.
  56.  Ju S, Tan L, Su W, Rong K. Interventional effect of berberine liposome 
on impaired glucose tolerance accompanied with hyperlipemia. Journal 
of Practical Traditional Chinese Medicine. 2007;23(8):490–492.